The growth in the historic period can be attributed to increasing prevalence of chronic kidney disease, rising chemotherapy-induced anemia cases, adoption of biologic anemia therapies, expansion of dialysis treatment centers, improved access to prescription anemia drugs.
The growth in the forecast period can be attributed to increasing focus on personalized anemia management, rising adoption of biosimilar alternatives, expansion of chronic disease treatment programs, growing emphasis on patient quality of life, increased investments in biologic drug optimization. Major trends in the forecast period include increasing use of erythropoiesis-stimulating agents, rising demand for anemia management therapies, expansion of oncology supportive care treatments, growing focus on reducing blood transfusions, enhanced monitoring of chronic anemia conditions.
The increasing prevalence of anemia is expected to drive the growth of the Procrit market moving forward. Anemia is a medical condition characterized by a deficiency of healthy red blood cells or hemoglobin, leading to reduced oxygen delivery to tissues. The prevalence of anemia is rising due to factors such as the growing global burden of chronic diseases like kidney failure, cancer, and inflammatory disorders, as well as poor nutrition, which results in deficiencies of iron, vitamin B12, and folate. Procrit (epoetin alfa) is used to treat anemia caused by chronic kidney disease, chemotherapy, or certain treatments for HIV. It works by stimulating red blood cell production, thereby reducing the need for blood transfusions in patients with low hemoglobin levels. For example, in December 2024, the National Center for Health Statistics, a US-based government agency, reported that the prevalence of anemia in individuals aged 2 years and older increased by 9.3% in 2023. As a result, the increasing prevalence of anemia is driving the growth of the Procrit market.
The increasing prevalence of chronic kidney diseases is expected to drive the growth of the Procrit market in the future. Chronic kidney disease is a condition where the kidneys gradually lose their ability to filter waste products from the blood. The prevalence of chronic kidney diseases is rising due to factors such as aging populations, obesity, lifestyle factors, and environmental exposures. Procrit (epoetin alfa) is used in patients with chronic kidney disease to treat anemia by stimulating red blood cell production, helping maintain adequate hemoglobin levels, and reducing the need for blood transfusions. For example, in June 2023, a report from Kidney Research UK, a UK-based non-profit organization, stated that approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages of the disease, while an additional 3.9 million are in the early stages. By 2033, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million. Therefore, the increase in the prevalence of chronic kidney diseases is driving the growth of the Procrit market.
The rising incidence of cancer is also expected to boost the Procrit market in the future. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade and destroy normal tissues, potentially leading to death if not treated. The incidence of cancer is rising due to factors such as an aging population, increased exposure to risk factors like smoking, obesity, and environmental pollutants, lifestyle changes, and improved diagnostic capabilities that allow for earlier and more accurate cancer detection. Procrit (epoetin alfa) is used to treat anemia in cancer patients undergoing chemotherapy by increasing red blood cell production, improving energy levels, and reducing the need for blood transfusions. For instance, in August 2024, the Australian Institute of Health and Welfare, an Australian government agency for health and welfare statistics, projected that by 2034, Australia would see approximately 209,000 new cancer diagnoses, a significant increase from the 169,000 cases expected in 2024. This growth reflects the impact of an aging population and rising cancer rates. Additionally, in 2024, cancer is expected to account for about 3 out of every 10 deaths in the country. Therefore, the rising incidence of cancer is driving the growth of the Procrit market.
Major companies operating in the procrit market are Amgen Inc.
North America was the largest region in the procrit market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the procrit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the procrit market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the procrit market by increasing costs of imported active ingredients, biologic manufacturing inputs, prefilled syringe components, and temperature-controlled distribution services. Hospitals and outpatient clinics in North America and Europe are most affected due to dependence on imported biologics, while Asia-Pacific faces higher costs in contract manufacturing and supply logistics. These tariffs are contributing to pricing pressures and reimbursement challenges. However, they are also encouraging domestic biologics production, regional manufacturing partnerships, and supply chain localization for critical anemia therapies.
The procrit market research report is one of a series of new reports that provides procrit market statistics, including procrit industry global market size, regional shares, competitors with a procrit market share, detailed procrit market segments, market trends and opportunities, and any further data you may need to thrive in the procrit industry. This procrit market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Procrit is a brand name for epoetin alfa, a prescription medication used to treat anemia caused by various conditions. It is a synthetic version of erythropoietin, a hormone naturally produced by the kidneys that stimulates the bone marrow to produce red blood cells. Procrit is commonly prescribed for anemia associated with chronic kidney disease, anemia resulting from chemotherapy in patients with non-myeloid cancers, anemia in patients with HIV or AIDS receiving zidovudine, and anemia in patients scheduled for elective surgery to reduce the need for blood transfusions.
The primary indications for Procrit are chronic kidney disease, human immunodeficiency virus (HIV) infection, and chemotherapy. Chronic kidney disease refers to a condition in which the kidneys gradually lose their ability to filter waste products from the blood. Procrit is distributed through direct sales, pharmaceutical wholesalers, and retail pharmacies, and is used by a variety of end users, including hospitals, outpatient clinics, and home care providers.
The procrit market consists of sales of epoetin alfa injections, pre-filled pens, and monitoring products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing focus on personalized anemia management, rising adoption of biosimilar alternatives, expansion of chronic disease treatment programs, growing emphasis on patient quality of life, increased investments in biologic drug optimization. Major trends in the forecast period include increasing use of erythropoiesis-stimulating agents, rising demand for anemia management therapies, expansion of oncology supportive care treatments, growing focus on reducing blood transfusions, enhanced monitoring of chronic anemia conditions.
The increasing prevalence of anemia is expected to drive the growth of the Procrit market moving forward. Anemia is a medical condition characterized by a deficiency of healthy red blood cells or hemoglobin, leading to reduced oxygen delivery to tissues. The prevalence of anemia is rising due to factors such as the growing global burden of chronic diseases like kidney failure, cancer, and inflammatory disorders, as well as poor nutrition, which results in deficiencies of iron, vitamin B12, and folate. Procrit (epoetin alfa) is used to treat anemia caused by chronic kidney disease, chemotherapy, or certain treatments for HIV. It works by stimulating red blood cell production, thereby reducing the need for blood transfusions in patients with low hemoglobin levels. For example, in December 2024, the National Center for Health Statistics, a US-based government agency, reported that the prevalence of anemia in individuals aged 2 years and older increased by 9.3% in 2023. As a result, the increasing prevalence of anemia is driving the growth of the Procrit market.
The increasing prevalence of chronic kidney diseases is expected to drive the growth of the Procrit market in the future. Chronic kidney disease is a condition where the kidneys gradually lose their ability to filter waste products from the blood. The prevalence of chronic kidney diseases is rising due to factors such as aging populations, obesity, lifestyle factors, and environmental exposures. Procrit (epoetin alfa) is used in patients with chronic kidney disease to treat anemia by stimulating red blood cell production, helping maintain adequate hemoglobin levels, and reducing the need for blood transfusions. For example, in June 2023, a report from Kidney Research UK, a UK-based non-profit organization, stated that approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages of the disease, while an additional 3.9 million are in the early stages. By 2033, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million. Therefore, the increase in the prevalence of chronic kidney diseases is driving the growth of the Procrit market.
The rising incidence of cancer is also expected to boost the Procrit market in the future. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, which can invade and destroy normal tissues, potentially leading to death if not treated. The incidence of cancer is rising due to factors such as an aging population, increased exposure to risk factors like smoking, obesity, and environmental pollutants, lifestyle changes, and improved diagnostic capabilities that allow for earlier and more accurate cancer detection. Procrit (epoetin alfa) is used to treat anemia in cancer patients undergoing chemotherapy by increasing red blood cell production, improving energy levels, and reducing the need for blood transfusions. For instance, in August 2024, the Australian Institute of Health and Welfare, an Australian government agency for health and welfare statistics, projected that by 2034, Australia would see approximately 209,000 new cancer diagnoses, a significant increase from the 169,000 cases expected in 2024. This growth reflects the impact of an aging population and rising cancer rates. Additionally, in 2024, cancer is expected to account for about 3 out of every 10 deaths in the country. Therefore, the rising incidence of cancer is driving the growth of the Procrit market.
Major companies operating in the procrit market are Amgen Inc.
North America was the largest region in the procrit market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the procrit market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the procrit market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the procrit market by increasing costs of imported active ingredients, biologic manufacturing inputs, prefilled syringe components, and temperature-controlled distribution services. Hospitals and outpatient clinics in North America and Europe are most affected due to dependence on imported biologics, while Asia-Pacific faces higher costs in contract manufacturing and supply logistics. These tariffs are contributing to pricing pressures and reimbursement challenges. However, they are also encouraging domestic biologics production, regional manufacturing partnerships, and supply chain localization for critical anemia therapies.
The procrit market research report is one of a series of new reports that provides procrit market statistics, including procrit industry global market size, regional shares, competitors with a procrit market share, detailed procrit market segments, market trends and opportunities, and any further data you may need to thrive in the procrit industry. This procrit market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Procrit is a brand name for epoetin alfa, a prescription medication used to treat anemia caused by various conditions. It is a synthetic version of erythropoietin, a hormone naturally produced by the kidneys that stimulates the bone marrow to produce red blood cells. Procrit is commonly prescribed for anemia associated with chronic kidney disease, anemia resulting from chemotherapy in patients with non-myeloid cancers, anemia in patients with HIV or AIDS receiving zidovudine, and anemia in patients scheduled for elective surgery to reduce the need for blood transfusions.
The primary indications for Procrit are chronic kidney disease, human immunodeficiency virus (HIV) infection, and chemotherapy. Chronic kidney disease refers to a condition in which the kidneys gradually lose their ability to filter waste products from the blood. Procrit is distributed through direct sales, pharmaceutical wholesalers, and retail pharmacies, and is used by a variety of end users, including hospitals, outpatient clinics, and home care providers.
The procrit market consists of sales of epoetin alfa injections, pre-filled pens, and monitoring products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Procrit Market Characteristics
3. Procrit Market Supply Chain Analysis
4. Global Procrit Market Trends and Strategies
5. Procrit Market Analysis of End Use Industries
7. Global Procrit Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Procrit Total Addressable Market (TAM) Analysis for the Market
9. Procrit Market Segmentation
10. Procrit Market Regional and Country Analysis
11. Asia-Pacific Procrit Market
12. China Procrit Market
13. India Procrit Market
14. Japan Procrit Market
15. Australia Procrit Market
16. South Korea Procrit Market
17. Western Europe Procrit Market
18. UK Procrit Market
19. Germany Procrit Market
20. France Procrit Market
21. Eastern Europe Procrit Market
22. North America Procrit Market
23. USA Procrit Market
24. Canada Procrit Market
25. South America Procrit Market
26. Middle East Procrit Market
27. Africa Procrit Market
29. Procrit Market Competitive Landscape and Company Profiles
32. Procrit Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Procrit Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses procrit market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for procrit? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The procrit market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indications: Chronic Kidney Diseases; Human Immunodeficiency Virus (HIV) Infection; Chemotherapy2) By Distribution Channel: Direct Sales; Pharmaceutical Wholesalers; Retail Pharmacies
3) By End Users: Hospitals; Outpatient Clinics; Home Care
Companies Mentioned: Amgen Inc.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Procrit market report include:- Amgen Inc.
